Keymed Biosciences Inc. announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Appl...
Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; “Axcelead DDP”) announced that it has entered into a drug discovery se...
Keymed Biosciences Inc. (HKEX: 02162) announced the National Medical Products Administration (the "NMPA") of China has recently approved the supp...
Bristol Myers Squibb (NYSE: BMY) announced results from POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055), the pivotal Phase 3 trials evalua...
What are "Novel" Drugs? "Novel" drugs are new drugs never before approved or marketed in the U.S. The term "novel" drugs refers to medications ...
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), announced that the first patient has been dosed in the pivotal Phase 3 Aspire study (NCT06617429) ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage Parkinson&rs...
In an interaction with BioPharma BoardRoom, Saurabh Singal, CEO & Founder of MoleculeAI, discusses how their generative AI-driven tools...
HUB internationally recognized pioneer in organoid development Acquisition expands Merck’s 2D and 3D cell culture portfolio Organ...
Viatris Inc. (NASDAQ: VTRS) announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of ceneri...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it has received CE mark approval for its cobas® Mass Spec solution including the cobas® i 601 ana...
Eli Lilly and Company (NYSE: LLY) announced that the National Medical Products Administration (NMPA) in China has approved Kisunla...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics L...
Sandoz takes further steps to resolve legacy US generic drug antitrust class action litigation Sandoz US has entered into a settlement agreement with ...
© 2025 Biopharma Boardroom. All Rights Reserved.
